Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Kelly Anne Phillips

Showing results (81-90 of 156) with videos related to

Pageof 16
Sort By:
British Journal of Cancer|February 18, 2021
Survival from breast cancer in women with a BRCA2 mutation by treatmentD Gareth Evans, Kelly-Anne Phillips, Roger L Milne, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|December 8, 2011
Breast cancer prognosis in BRCA1 and BRCA2 mutation carriers: an International Prospective Breast Cancer Family Registry population-based cohort studyPamela J Goodwin, Kelly-Anne Phillips, Dee W West, et al.
American Journal of Epidemiology|April 12, 2017
Testing for Gene-Environment Interactions Using a Prospective Family Cohort Design: Body Mass Index in Early and Later Adulthood and Risk of Breast CancerGillian S Dite, Robert J MacInnis, Adrian Bickerstaffe, et al.
Cancer Epidemiology, Biomarkers & Prevention : a Publication of the American Association for Cancer Research, Cosponsored by the American Society of Preventive Oncology|June 10, 2009
Prediagnosis reproductive factors and all-cause mortality for women with breast cancer in the breast cancer family registryKelly-Anne Phillips, Roger L Milne, Dee W West, et al.
Nature Cancer|August 25, 2022
Checkpoint inhibitor immunotherapy diminishes oocyte number and quality in miceAmy L Winship, Lauren R Alesi, Sneha Sant, et al.
Gynecologic Oncology|November 25, 2019
Prospective follow-up of quality of life for participants undergoing risk-reducing salpingo-oophorectomy or ovarian cancer screening in GOG-0199: An NRG Oncology/GOG studyPhuong L Mai, Helen Q Huang, Lari B Wenzel, et al.
BMC Medicine|March 3, 2026
Risks of non-breast, non-ovarian cancers for BRCA1 and BRCA2 pathogenic variant carriers: a prospective cohort studyRuotong Yang, Robert J MacInnis, Roger L Milne, et al.
Journal of the National Cancer Institute|January 20, 2022
Oral Contraceptive Use in BRCA1 and BRCA2 Mutation Carriers: Absolute Cancer Risks and BenefitsLieske H Schrijver, Thea M Mooij, Anouk Pijpe, et al.
The Lancet. Oncology|October 5, 2023
Measuring ovarian toxicity in clinical trials: an American Society of Clinical Oncology research statementWanda Cui, Rodney P Rocconi, Ramya Thota, et al.
JNCI Cancer Spectrum|April 28, 2020
Risk-Reducing Salpingo-Oophorectomy and Breast Cancer Risk Reduction in the Gynecologic Oncology Group Protocol-0199 (GOG-0199)Phuong L Mai, Austin Miller, Mitchell H Gail, et al.
Pageof 16

Showing results (81-90 of 156) with videos related to

Sort By:
Pageof 16
British Journal of Cancer|February 18, 2021
Survival from breast cancer in women with a BRCA2 mutation by treatmentD Gareth Evans, Kelly-Anne Phillips, Roger L Milne, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|December 8, 2011
Breast cancer prognosis in BRCA1 and BRCA2 mutation carriers: an International Prospective Breast Cancer Family Registry population-based cohort studyPamela J Goodwin, Kelly-Anne Phillips, Dee W West, et al.
American Journal of Epidemiology|April 12, 2017
Testing for Gene-Environment Interactions Using a Prospective Family Cohort Design: Body Mass Index in Early and Later Adulthood and Risk of Breast CancerGillian S Dite, Robert J MacInnis, Adrian Bickerstaffe, et al.
Cancer Epidemiology, Biomarkers & Prevention : a Publication of the American Association for Cancer Research, Cosponsored by the American Society of Preventive Oncology|June 10, 2009
Prediagnosis reproductive factors and all-cause mortality for women with breast cancer in the breast cancer family registryKelly-Anne Phillips, Roger L Milne, Dee W West, et al.
Nature Cancer|August 25, 2022
Checkpoint inhibitor immunotherapy diminishes oocyte number and quality in miceAmy L Winship, Lauren R Alesi, Sneha Sant, et al.
Gynecologic Oncology|November 25, 2019
Prospective follow-up of quality of life for participants undergoing risk-reducing salpingo-oophorectomy or ovarian cancer screening in GOG-0199: An NRG Oncology/GOG studyPhuong L Mai, Helen Q Huang, Lari B Wenzel, et al.
BMC Medicine|March 3, 2026
Risks of non-breast, non-ovarian cancers for BRCA1 and BRCA2 pathogenic variant carriers: a prospective cohort studyRuotong Yang, Robert J MacInnis, Roger L Milne, et al.
Journal of the National Cancer Institute|January 20, 2022
Oral Contraceptive Use in BRCA1 and BRCA2 Mutation Carriers: Absolute Cancer Risks and BenefitsLieske H Schrijver, Thea M Mooij, Anouk Pijpe, et al.
The Lancet. Oncology|October 5, 2023
Measuring ovarian toxicity in clinical trials: an American Society of Clinical Oncology research statementWanda Cui, Rodney P Rocconi, Ramya Thota, et al.
JNCI Cancer Spectrum|April 28, 2020
Risk-Reducing Salpingo-Oophorectomy and Breast Cancer Risk Reduction in the Gynecologic Oncology Group Protocol-0199 (GOG-0199)Phuong L Mai, Austin Miller, Mitchell H Gail, et al.
Pageof 16